Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
5 clinical trials · Condition
◉ Watch Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Record | Firm | Date |
|---|---|---|
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas (NCT04074746) | M.D. Anderson Cancer Center | 2020-07-18 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998) | City of Hope Medical Center | 2019-02-04 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732) | M.D. Anderson Cancer Center | 2012-10-29 |
Track Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified automatically
Every clearance here is in the API, with alerts when new ones post.